GI Partners Completes Acquisition of the CDMO and Cell Solutions Businesses from Charles River Laboratories and forms Rose BioSolutions

GI Partners has finalized the acquisition of the Contract Development and Manufacturing Organization (CDMO) and Cell Solutions businesses from Charles River Laboratories International, Inc., establishing Rose BioSolutions as a standalone leader in advanced therapy manufacturing. The deal, announced on May 7, 2026, involves an undisclosed amount and positions Rose Bio to deliver comprehensive end-to-end solutions in the rapidly evolving cell and gene therapy sector.

The formation of Rose BioSolutions marks a strategic move to capitalize on the growing demand for advanced therapies, particularly in the areas of cell and gene therapy. As a dedicated entity, Rose Bio combines the expertise of its predecessor businesses with the backing of GI Partners to focus on innovation and operational efficiency. The company aims to enhance its capabilities in plasmid DNA, viral vector, and cell therapy manufacturing, thereby addressing a critical need in the market for integrated solutions that streamline the development and production processes.

Rose Bio is committed to providing reliable and scalable services, guided by its R.O.S.E. standard, which emphasizes outcome-driven client service. This focus on quality and reliability is essential as the biotechnology landscape continues to evolve, with increasing pressure on companies to deliver therapies more efficiently. The leadership team at Rose Bio, including Ahmad Hussin, Global Head of CDMO, underscores the importance of having a trusted partner throughout the research, development, and manufacturing stages, which is vital for advancing therapeutic programs to market.

The transaction reflects broader trends in the healthcare sector, where the demand for advanced therapies is on the rise. As the industry shifts towards more personalized medicine, companies like Rose Bio are well-positioned to meet the needs of biopharmaceutical clients seeking comprehensive support. The integration of CDMO and Cell Solutions capabilities under one roof allows for a seamless transition from raw materials to finished therapies, enhancing the overall client experience and accelerating time-to-market for new treatments.

Looking ahead, the establishment of Rose BioSolutions could have significant implications for the healthcare market. As the demand for cell and gene therapies continues to grow, the need for specialized manufacturing partners will likely increase. Rose Bio's focus on delivering high-quality, reliable solutions positions it as a key player in the sector, potentially influencing competitive dynamics and driving further innovation in advanced therapy manufacturing. The backing from GI Partners also suggests a commitment to long-term growth and investment in new capabilities, which may enhance Rose Bio's standing in the marketplace.